A new study published in the Journal of Internal Medicine (vol. 15, no. 7) shows that samples handed out by pharmaceutical sales representatives may influence doctors to prescribe drugs they wouldn't have otherwise.
A new study published in the Journal of Internal Medicine (vol. 15, no. 7) shows that samples handed out by pharmaceutical sales representatives may influence doctors to prescribe drugs they wouldn't have otherwise.
The cross-sectional survey of 154 general medicine and family physicians was conducted to determine why and under what circumstances physicians dispense drug samples, if drug samples lead doctors to use medications other than those they normally prescribe and what type of physicians use drug samples.
Of a total of 131 respondents out of 154 surveyed, 17% of physicians reported that they would dispense a drug sample to an insured woman with an uncomplicated lower urinary tract infection. Of those, 95% reported that they would dispense a sample that differed from their normal drug of choice. Twenty-seven percent of respondents said they would dispense a drug sample to an uninsured man with hypertension. Of those, 91% said they would sample a drug that differed from their normal drug of choice. And, when presented with an uninsured woman with depression, 82% of respondents reported they would dispense a drug sample; of those, 49% said they would dispense a drug that differed from their drug of choice.
According to the survey, avoiding cost to the patient was the most frequent reason given for dispensing a drug sample. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.